66384dddf377e.pdf
DOI:
Mavjud emas
1. Lizneva D., Suturina L., Walker W., Brakta S., Gavrilova-Jordan L., Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertilityand Sterility. 2016;106(1):6– 15
2. Simon Walker, Geoffrey Beckett, Pater Rae, Peter Ashby. (Ed.) (2013).WHITBY'S CLINICAL BIOCHEMISTRY Lecture Notes. 9Th editions. UK. John Wiley &Sons. 141- 147.
3. Tayrab, E., Ali ,M., Modawe, G.A., Naway, L(2014). Serum Anti-Müllerian hormone as laboratory predictor in infertile women with and without polycystic ovary syndrome. 2(3):61-6.
4. William J Marshall, Stephen K, Bangert Marta Lapsley. (2012). Clinical chemistry, seventh edition. China. Elsevier.258-272.
5. Lergo ,R., Kunselman, A., Dunaif, A(2001).Prevelence and predictors of dyslipidaemia in women with polycystic ovary syndrome, Am JMed., 111: 607-613.